Abstract
Rationale
To our knowledge, only a few double-blind randomized controlled trials with antipsychotic drugs have been conducted to examine the treatment of methamphetamine-induced psychosis (MAP).
Objectives
The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic disorder, in individuals with MAP.
Methods
Eighty individuals with MAP were randomly assigned into two groups, i.e. treatment with quetiapine (n = 36) and haloperidol (n = 44). Sixty-eight patients (85 %) completed the study protocol, i.e. treatment with quetiapine at least 100 mg per day or haloperidol at least 2 mg per day orally once a day for 4 weeks. The doses were increased every 5 days until no psychotic symptom was observed from the Positive and Negative Syndrome Scale (PANSS). Data were analysed by survival analysis with Cox’s proportional regression analysis, general estimating equations and log-rank tests.
Results
Thirty-two (89 %) subjects from the quetiapine group and 37 subjects (84 %) from the haloperidol group met the remission criteria at the end of the study. Baseline PANSS total scores of quetiapine and haloperidol groups were 82.4 ± 16.6 and 90.0 ± 18.4, respectively (mean ± SD; p = 0.06). The change-from-baseline scores were −47.8 for the quetiapine group and −53.2 for the haloperidol group. There were no significant differences between the antipsychotic effects (coefficient value = −2.6, p = 0.32, 95%CI = −7.6, 2.5) and the adverse effects of quetiapine and haloperidol.
Conclusions
Quetiapine may be used as an antipsychotic treatment for MAP with comparable therapeutic effects and adverse events to treatment with classical antipsychotic drugs.
Similar content being viewed by others
References
Berk M, Brook S, Trandafir AI (1999) A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 14:177–180
Booij J, van Amelsvoort T (2012) Imaging as a tool to investigate psychoses and antipsychotics. Handb Exp Pharmacol 212:299–337
Bramnes JG, Gundersen O, Guterstam J, Rognli EB, Konstenius M, Loberg EM, Medhus S, Tanum L, Franck J (2012) Amphetamine-induced psychosis – a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 2012:221
Brown ES, Nejtek VA, Perantie DC, Bobadilla L (2002) Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 4:406–411
Brown ES, Nejtek VA, Perantie DC, Rajan Thomas N, Rush AJ (2003) Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol 23:384–388
Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remiao F, Carvalho F, Bastos MD (2012) Toxicity of amphetamines: an update. Arch Toxicol 6:6
Connell PH (1958) Amphetamine psychosis. Oxford University Press, London
Crews FT, Boettiger CA (2009) Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Behav 93:237–247
Crossley NA, Constante M, McGuire P, Power P (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196:434–439
Curran C, Byrappa N, McBride A (2004) Stimulant psychosis: systematic review. Br J Psychiatry 185:196–204
Dossenbach M, Erol A, el Mahfoud Kessaci M, Shasheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I, IC-SOHO Study Group (2004) Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65:312–321
Horacek J, Budenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C (2006) Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20:389–409
Kalayasiri R, Mutirangura A, Verachai V, Gelernter J, Malison RT (2009) Risk factors for methamphetamine-induced paranoia and latency of symptom onset in a Thai drug treatment cohort. Asian Biomed 3:635–643
Kariya S, Isozaki S, Masubuchi Y, Suzuki T, Narimatsu S (1995) Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine. Biochem Pharmacol 50:1645–1650
Kennedy A, Wood AE, Saxon AJ, Malte C, Harvey M, Jurik J, Kilzieh N, Lofgreen C, Tapp A (2008) Quetiapine for the treatment of cocaine dependence: an open-label trial. J Clin Psychopharmacol 28:221–224
Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S (2010) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. doi:10.1002/14651858.CD006625.pub3
Kuroki T, Nagao N, Nakahara T (2008) Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 172:199–212
Leelahanaj T, Kongsakon R, Netrakom P (2005) A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thail 88:S43–S52
McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J (2005) Quetiapine or haloperidol as monotherapy for bipolar mania – a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 15:573–585
McKetin R, Ross J, Kelly E, Baker A, Lee N, Lubman DI, Mattick R (2008) Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants. Drug Alcohol Rev 27:277–285
Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L (2008) Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 23:417–424
Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233–255
Meltzer HY, Sumiyoshi T (2008) Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 195:98–102
Nejtek VA, Avila M, Chen LA, Zielinski T, Djokovic M, Podawiltz A, Kaiser K, Bae S, Rush AJ (2008) Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. J Clin Psychiatry 69:1257–1266
Nichaikovit T, Uneanong S, Kessawai D, Thomyangkoon P (2000) The Thai version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia: criterion validity and interrater reliability. J Med Assoc Thail 83:646–651
Nishikawa T, Mataga N, Takashima M, Toru M (1983) Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment. Eur J Pharmacol 88:195–203
Ozbilen M, Adams CE, Marley J (2012) Anticholinergic effects of oral antipsychotic drugs of typicals versus atypicals over medium- and long-term: systematic review and meta-analysis. Curr Med Chem 19:5214–5218
Potvin S, Stip E, Roy JY (2003) Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 18:121–132
Ray LA, Chin PF, Heydari A, Miotto K (2011) A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving. Psychopharmacology (Berlin) 217:341–351
Rizkallah E, Stip E, Zhornitsky S, Pampoulova T, Gendron A, Rompré PP, Chiasson JP, Potvin S (2010) Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opin Pharmacother 11:2947–2951
Sato M, Chen CC, Akiyama K, Otsuki S (1983) Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 18:429–440
Sattar SP, Bhatia SC, Petty F (2004) Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 29:452–457
Sayers SL, Campbell EC, Kondrich J, Mann SC, Cornish J, O'Brien C, Caroff SN (2005) Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 193:379–386
Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27–38
Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206–1214
Shoptaw SJ, Kao U, Ling W (2009) Treatment for amphetamine psychosis. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003026.pub3
Smelson DA, Ziedonis D, Williams J, Losonczy MF, Williams J, Steinberg ML, Kaune M (2006) The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 26:9–12
Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M (2003) Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol 6:347–352
Srisurapanont M, Kittirattanapaiboon P, Jarusuraisin N (2001) Treatment for amphetamine psychosis. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003026
Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N (2013) Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. doi:10.1002/14651858.CD007815.pub2
Thanyarak Institute (2012) Substance statistics at Thanyarak Institute (in Thai). Retrieved from http://www.thanyarak.go.th
Tillmann HC, Sharpe N, Sponer G, Wehling M (2001) Does intention-to-treat analysis answer all questions in long-term mortality trials? Considerations on the basis of the ANZ trial. Int J Clin Pharmacol Ther 39:205–212
Timdahl K, Carlsson A, Stening G (2007) An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol 22:315–325
Tong J, Ross BM, Schmunk GA, Peretti FJ, Kalasinsky KS, Furukawa Y, Ang LC, Aiken SS, Wickham DJ, Kish SJ (2003) Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. Am J Psychiatry 160:896–903
UNODC (2012) World drug report 2012 (United Nations publication), Sales No. E.12.XI.1
Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, Wong CT, Hoffman W, Jayne M, Alia-Klein N, Thanos P, Fowler JS (2012) Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17:918–925
Yui K, Ishiguro T, Goto K, Ikemoto S, Kamata Y (1999) Spontaneous recurrence of methampetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change. Eur Arch Psychiatry Clin Neurosci 249:103–111
Zhornitsky S, Rizkallah E, Pampoulova T, Chiasson JP, Stip E, Rompre PP, Potvin S (2010) Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychiatry 30:417–424
Acknowledgments
This study was funded by the National Research Council of Thailand (NRCT). RK is supported for conducting research by the mid-career researcher grant (RMU5380025) co-funded by the Thailand Research Fund (TRF), the Office of the Higher Education Commission of Thailand, Chulalongkorn University and the Faculty of Medicine, Chulalongkorn University and the D43 TW006166. The experiments comply with the current Thai laws.
Conflict of interest
None of the authors have had a financial relationship with the organization that sponsored the research. The study is not supported by, nor any income received, from a commercial sponsor.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verachai, V., Rukngan, W., Chawanakrasaesin, K. et al. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacology 231, 3099–3108 (2014). https://doi.org/10.1007/s00213-014-3485-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-014-3485-6